MAP2K7 and angiosarcoma: Indeed, we found that MAPK activation was present by IHC in over half of clinical angiosarcoma samples and that treatment with either the MEK inhibitor trametinib or pan-VEGFR inhibitor cediranib decreased the viability of cultured angiosarcoma cell lines.